Middle East and Africa (MEA) Flu Diagnostic and Treatment Market - Strategic Insights and Forecasts (2026-2031)

The Middle East and Africa (MEA) flu diagnostic and treatment market is projected to register a strong CAGR during the forecast period (2026-2031).

Key Highlights

Market Overview

The need for flu diagnostics and treatment is shaped by seasonal outbreaks, respiratory disease surveillance, hospital admission pressure, and the need to distinguish influenza from infections with similar symptoms. Purchasing decisions increasingly weigh turnaround time, analytical performance, workflow fit, reagent supply, and the ability to test several respiratory pathogens from one sample.

WHO data shows that influenza surveillance remains uneven across the Middle East. In the Eastern Mediterranean Region, 15 of 22 countries reported influenza-like illness or severe acute respiratory infection surveillance, while 16 centres were designated as national influenza centres and 13 had functional capacity to isolate influenza virus. This creates a two-speed market: higher-income health systems can support molecular and multiplex testing, while resource-constrained systems often depend more heavily on centralized laboratories and targeted surveillance.

Clinical demand also varies by season and virus type. WHO reported increased influenza activity in the Eastern Mediterranean Region during October 2025, with A(H3N2) predominant in the Arabian Peninsula and A(H1N1)pdm09 more prevalent in northern parts of the region. South Africa's 2025 season was dominated by A(H3N2), showing why regional laboratories need current strain surveillance rather than relying on a fixed diagnostic profile.

For suppliers, value is moving toward systems that connect accurate testing with rapid clinical decisions. Hospitals and laboratories increasingly require platforms that can handle seasonal volume changes without excessive manual work. Multiplex molecular systems therefore compete not only on detection performance, but also on sample processing, connectivity, automation, assay menu, and total cost per result.

Key Market Indicators

Market Drivers

Expansion of influenza surveillance and laboratory networks. WHO's Eastern Mediterranean surveillance program has expanded ILI and SARI monitoring, while the African regional network continues to collect and test specimens across multiple countries. In Week 44 of 2025, 19 African countries contributed surveillance data and 1,447 specimens were tested for influenza. Wider surveillance creates recurring demand for molecular assays, reference laboratory services, sample logistics, and quality-control systems. It also raises the value of tests that can identify influenza A and B alongside other respiratory pathogens.

Clinical need to distinguish influenza from other respiratory infections. Influenza, RSV, and SARS-CoV-2 can present with overlapping symptoms, limiting the reliability of symptom-based diagnosis. Roche's cobas liat platform, Hologic's Panther Fusion assays, BD's respiratory portfolio, and bioMérieux's BIOFIRE panels reflect buyer demand for tests that differentiate several pathogens from a single specimen. Faster results are especially relevant in emergency departments, outpatient clinics, and hospitals where treatment and isolation decisions must be made during the patient encounter.

Greater focus on timely antiviral treatment. Diagnostic timing affects whether clinicians can make treatment decisions early enough to provide clinical benefit, particularly for patients at higher risk of complications. Saudi Arabia's Ministry of Health identifies older adults, young children, pregnant women, people with chronic diseases, immunocompromised patients, and healthcare workers among groups requiring particular protection. This creates demand for testing pathways that can support targeted treatment rather than relying solely on clinical symptoms.

Seasonal vaccination and preparedness programs are strengthening the wider influenza ecosystem. Saudi Arabia expanded access to seasonal influenza vaccination through its Sehhaty application and is also developing local influenza vaccine manufacturing capability. In October 2025, CSL Seqirus and Vaccine Industrial Company signed an agreement framework with the Saudi Ministry of Health to localize cell-based seasonal and pandemic influenza vaccine manufacturing and establish pandemic vaccine preparedness arrangements. Such programs can increase institutional attention to influenza surveillance, diagnosis, stock planning, and treatment readiness.

Market Restraints and Challenges

Uneven laboratory capacity across countries. The Eastern Mediterranean Region has 16 designated national influenza centres, but only 13 were reported as functional for influenza virus isolation. African surveillance participation also varies by epidemiological week. This uneven capacity limits the reach of higher-value molecular testing and can shift purchasing toward centralized reference laboratories rather than distributed point-of-care networks. Suppliers must therefore adapt equipment placement, technical support, reagent logistics, and training to widely different healthcare infrastructures.

High operating demands for molecular testing. Molecular platforms require trained staff, controlled workflows, reliable sample handling, equipment maintenance, and uninterrupted reagent supply. These conditions can be difficult for smaller laboratories and facilities outside large urban healthcare networks. Automated systems reduce manual steps, but buyers still need suitable infrastructure and service support. The commercial effect is a preference for platforms that combine automation with broad assay menus and manageable operating requirements.

Limited affordability in parts of Africa. Healthcare budgets differ sharply across the region, and influenza testing competes with tuberculosis, malaria, HIV, maternal health, and other public-health priorities. Routine molecular testing can therefore face stricter economic review where influenza surveillance is not integrated into broader respiratory testing programs. Suppliers seeking wider penetration may need centralized procurement models, tiered testing strategies, or platforms capable of serving several respiratory indications rather than influenza alone.

Seasonal demand creates capacity and inventory pressure. Influenza testing volumes can rise sharply during local transmission periods and fall outside those periods. Laboratories must balance reagent availability against the risk of unused inventory, while distributors must manage import lead times and local registration requirements. Platforms with flexible respiratory assay menus can reduce this exposure because the installed system can support testing for several pathogens when influenza demand is lower.

Major Segment Analysis

Molecular Tests / NAATs

Molecular Tests / NAATs represent a strategically important offering segment because they combine influenza detection with the ability to support broader respiratory testing workflows. WHO continues to maintain molecular diagnostic protocols for influenza, including multiplex approaches that can detect influenza and SARS-CoV-2 in the same reaction. This supports adoption where clinical accuracy, surveillance quality, and differentiation between respiratory pathogens justify laboratory investment.

Hospitals, reference laboratories, and higher-volume diagnostic centres are the most relevant buyers. Their purchasing criteria extend beyond analytical performance to throughput, automation, sample preparation, connectivity, service coverage, and assay availability. Roche's cobas liat, BD MAX, Hologic Panther Fusion, and bioMérieux BIOFIRE illustrate different ways suppliers address this requirement through automated molecular workflows and respiratory panels.

Regional Analysis

Saudi Arabia has one of the clearest institutional demand structures among the countries covered. The Ministry of Health operates seasonal influenza vaccination services through primary healthcare centres and the Sehhaty platform, while influenza prevention also forms part of health measures associated with Hajj. These programs create recurring demand for vaccination-related preparedness, clinical diagnosis, and surveillance capacity. The country's healthcare investment also supports adoption of automated laboratory systems where hospitals seek faster respiratory testing and standardized workflows.

Israel has a comparatively structured influenza surveillance environment. The Ministry of Health publishes regular respiratory-pathogen surveillance reports, while its National Center for Influenza and Respiratory Viruses serves as a reference facility for diagnosis in hospitalized patients. During the 2024-2025 season, influenza A and B strains were actively monitored, including A(H1N2)pdm09 and influenza B Victoria-lineage viruses. The combination of hospital surveillance, health-maintenance-organization vaccination, and laboratory monitoring supports demand for molecular and reference-laboratory diagnostics.

The UAE's market is supported by coordinated seasonal influenza programs. The Ministry of Health and Prevention launched its national seasonal influenza awareness campaign for the 2025-2026 season, with participation from federal and local health authorities. This structure favors suppliers that can support both centralized laboratory testing and decentralized clinical settings. Rapid diagnostic tests, molecular platforms, and respiratory panels can serve different points in the care pathway, while local regulatory registration and distribution remain important purchasing considerations.

Qatar represents a smaller but institutionally organized market in which purchasing is likely to remain concentrated among public healthcare organizations, hospitals, laboratories, and authorized distributors. The commercial opportunity is therefore less dependent on a large number of independent testing sites and more dependent on platform selection, public procurement, reagent continuity, and service coverage. Suppliers with broad respiratory assay menus can improve utilization because the same laboratory infrastructure can support testing beyond influenza during periods of lower flu activity.

Iran's position differs because access to imported diagnostic technologies can be affected by procurement and supply constraints. The country remains part of the wider WHO influenza surveillance framework, which supports the need for laboratory identification and monitoring of circulating viruses. Commercial development therefore depends not only on clinical demand, but also on the availability of instruments, reagents, replacement components, and local technical support. This increases the value of reliable supply channels and locally maintainable diagnostic capacity.

South Africa has the most established surveillance evidence among the African countries covered in the segmentation. NICD reported that the 2025 influenza season was dominated by A(H3N2) among subtyped influenza infections, while its 2026 surveillance has continued to track influenza A(H1N1)pdm09, A(H3N2), and influenza B. The 2026 season began in March, reinforcing the need for ongoing surveillance rather than a fixed annual testing schedule.

Egypt offers a different commercial profile. WHO and Egyptian health authorities have continued work to strengthen national surveillance for acute respiratory infections and improve capacity for influenza and other respiratory-virus monitoring. Egypt also has a long-established role in influenza surveillance, including monitoring of avian influenza. This supports demand for reference-laboratory testing, molecular diagnostics, sample processing, and surveillance infrastructure, although differences in healthcare resources can limit uniform adoption across the country.

Across these seven countries, purchasing priorities therefore differ materially. Saudi Arabia and the UAE place greater weight on organized prevention programs, hospital capability, and preparedness. Israel and South Africa have stronger surveillance-driven requirements for strain identification and laboratory monitoring. Egypt and Iran have greater relevance for capacity development and supply access, while Qatar offers a more concentrated procurement environment. These differences will shape product mix, distribution models, service requirements, and the relative adoption of rapid versus centralized molecular diagnostics through 2031.

Competitive Landscape

The competitive structure is technology-led and service-dependent, with international diagnostic companies competing through assay menus, automation, turnaround time, connectivity, and installed laboratory infrastructure. Roche, Abbott, Thermo Fisher Scientific, QuidelOrtho, bioMérieux, Danaher through Cepheid, Becton, Dickinson and Company, Hologic, QIAGEN, and Siemens Healthineers each address parts of the diagnostic workflow rather than competing through identical product models.

Roche combines near-patient molecular testing with respiratory multiplex assays, while BD and Hologic emphasize automated molecular workflows that can support wider respiratory menus. bioMérieux's BIOFIRE platform uses syndromic panels with broad pathogen coverage, which can improve the economic case for molecular testing when several respiratory pathogens need to be considered. QuidelOrtho competes more strongly in rapid point-of-care testing, including its QUICKVUE influenza and SARS test.

Barriers to entry include regulatory approvals, laboratory validation, distribution networks, installed instruments, technical service, and recurring reagent supply. Competition is therefore shaped by platform relationships and customer switching costs as much as by individual assay performance.

Recent Developments

• June 2026: Sinovac and Egyptian partner GENNVAX signed an agreement to localize influenza vaccine production, strengthening Egypt’s domestic manufacturing capacity and supporting national vaccine self-reliance and regional supply resilience efforts.

• May 2026: Roche and the Medicines Patent Pool signed a voluntary licence for Xofluza, enabling generic manufacturers to develop, produce, and supply baloxavir across 129 low- and middle-income countries.

• March 2026: Hologic's updated Panther Fusion SARS-CoV-2/Flu A/B/RSV documentation entered validity across several markets. The continued regulatory maintenance of the assay supports international availability of automated molecular respiratory testing and gives laboratories a broader response to seasonal volume changes.

• October 2025: CSL Seqirus and Vaccine Industrial Company signed an agreement framework with Saudi Arabia's Ministry of Health to localize cell-based seasonal and pandemic influenza vaccine manufacturing. The arrangement also addresses stockpiling and pandemic purchase commitments, linking local production with national preparedness.

Regulatory and Policy Environment

Influenza diagnostics in the region operate within national medical-device and in vitro diagnostic frameworks, while public-health laboratories follow WHO surveillance and laboratory guidance. WHO's Global Influenza Surveillance and Response System coordinates surveillance, virus sharing, and preparedness across member states. The system currently includes 166 institutions across 136 WHO Member States, providing the international framework behind national influenza surveillance.

Regulatory requirements affect market entry through product registration, laboratory validation, import controls, quality systems, and post-market obligations. These requirements can lengthen commercialization timelines, particularly when suppliers introduce molecular platforms or multiplex assays that require local clinical and technical assessment. WHO's updated molecular diagnosis information, revised in August 2025, also reflects the continuing need for standardized laboratory methods as influenza viruses change.

Public procurement and preparedness policy can materially change demand. Saudi Arabia's vaccination access and local manufacturing plans show how influenza policy can move beyond seasonal prevention toward supply security. In Africa, regional surveillance programs create a different route to demand by strengthening laboratory networks and specimen testing rather than relying mainly on commercial outpatient testing.

Outlook and Strategic Implications

The 2026-2031 market outlook will depend less on influenza incidence alone and more on how regional healthcare systems convert surveillance needs into routine testing capacity. Molecular and multiplex diagnostics should retain commercial relevance where hospitals need rapid differentiation of influenza from other respiratory infections. Point-of-care testing can capture demand in settings where centralized laboratory access is limited, but price, distribution, and regulatory access will remain important barriers.

Saudi Arabia's localization strategy could influence regional supply planning, while South Africa's surveillance infrastructure provides a model for sustained laboratory-based influenza monitoring. Across lower-resource markets, suppliers will need to align product economics with broader respiratory testing rather than depend on influenza-only demand.

• For diagnostic suppliers: Build regional service networks, local regulatory capability, and flexible respiratory assay menus alongside core influenza tests.

• For laboratories and hospitals: Prioritize platforms that balance turnaround time, throughput, assay breadth, reagent availability, and total operating cost.

• For distributors: Maintain seasonal inventory discipline and strengthen technical support because supply interruptions can become more acute during influenza peaks.

• For policymakers: Expand laboratory surveillance and integrate influenza testing with wider respiratory pathogen programs to improve use of limited healthcare resources.

• For investors and manufacturers: Monitor localization, public procurement, molecular testing adoption, and regional laboratory expansion as indicators of sustained commercial demand.

The market should therefore develop along two connected paths. Higher-income healthcare systems are likely to increase use of rapid molecular and multiplex testing, while many African markets will remain more dependent on centralized surveillance and targeted diagnostic capacity. Suppliers able to serve both models without excessive platform complexity should have the broadest route to regional growth through 2031.

Middle East and Africa (MEA) Flu Diagnostic and Treatment Market Scope: